<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109754</url>
  </required_header>
  <id_info>
    <org_study_id>2022-8261</org_study_id>
    <nct_id>NCT05109754</nct_id>
  </id_info>
  <brief_title>HOME NON-INVASIVE VENTILATION TARGETING EXPIRATORY FLOW LIMITATION IN SEVERE HYPERCAPNIC COPD.</brief_title>
  <official_title>HOME NON-INVASIVE VENTILATION TARGETING EXPIRATORY FLOW LIMITATION IN SEVERE HYPERCAPNIC COPD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this 2-phase pilot study, the BiPAP A40 EFL will be evaluated in patients with severe COPD&#xD;
      requiring home non-invasive ventilatory support with respect to patient-related and&#xD;
      physiologic outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective phase 1: in patients with COPD already established on home NIV, to assess the&#xD;
      effect of 2 months of the A40EFL on ventilator parameters, physiologic and patient-related&#xD;
      outcomes (PRO), in comparison to the patients' usual settings as prescribed by their treating&#xD;
      physician.&#xD;
&#xD;
      The two primary outcomes will be the nightly duration of NIV use and NIV-related symptoms&#xD;
      (S3-NIV questionnaire). Patient preference will be a secondary outcome.&#xD;
&#xD;
      Objective phase 2 : In hypercapnic patients with COPD with a prior hypercapnic exacerbation&#xD;
      requiring NIV in hospital, to obtain preliminary data regarding the impact of home NIV using&#xD;
      the A40EFL on COPD exacerbations and physiologic and patient-related outcomes.&#xD;
&#xD;
      The primary outcome will be the number of hospitalizations over 12 months on A40EFL.&#xD;
&#xD;
      Secondary outcomes will include descriptive data on number of exacerbations not requiring&#xD;
      hospitalization but treated with antibiotics or prednisone.&#xD;
&#xD;
      Additional secondary outcomes, physiologic and PRO, for both phases 1 &amp; 2, will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the nightly duration of NIV use</measure>
    <time_frame>2 months</time_frame>
    <description>(Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>S3-NIV questionnaire</measure>
    <time_frame>2 months</time_frame>
    <description>NIV-related symptoms (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>12 months</time_frame>
    <description>(phase 2)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>BPAP EFL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: use device for 2 months Phase 2: use device for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BiPAP EFL</intervention_name>
    <description>Non-invasive ventilation using a novel ventilatory mode targeting expiratory flow limitation in COPD</description>
    <arm_group_label>BPAP EFL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Phase 1:&#xD;
&#xD;
        severe COPD with FEV1&lt;50%, using home NIV successfully for at least 2 months through the&#xD;
        Quebec National Program for Home Ventilatory Assistance (NPHVA).&#xD;
&#xD;
          -  Phase 2:&#xD;
&#xD;
        severe COPD with FEV1&lt;50%; pCO2&gt;= 52 on arterial or capillary blood gas measured 2-4 weeks&#xD;
        after acute NIV use and discontinuation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Phase 1 COPD exacerbation requiring treatment (including hospitalization) within the&#xD;
             last 6 weeks; surgical procedure or major illness within the last 3 months;&#xD;
             kyphoscoliosis, neuromuscular disease, other lung disease (e.g. fibrosis); active&#xD;
             cancer; expected survival &lt; 2 months; listed on the transplant list.&#xD;
&#xD;
          -  Phase 2:&#xD;
&#xD;
        any additional condition potentially predisposing to hypercapnia such as: obesity (BMI&gt;&#xD;
        30kg/m2), kyphoscoliosis, neuromuscular disease, other lung disease (e.g. fibrosis), severe&#xD;
        obstructive sleep apnea (AHI&gt;30/h on prior testing if available, but will not test as part&#xD;
        of the study); active cancer; expected survival &lt; 2 months; listed on the transplant list&#xD;
        at start of study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Kaminska, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francine Noel, MD</last_name>
    <phone>514-934-1934</phone>
    <email>francine.noel@muhc.mcgill.ca</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Marta Kaminska</investigator_full_name>
    <investigator_title>Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercapnia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

